The Microbiotix team has extensive experience in small molecule anti-infective drug discovery and development.

Terry L. Bowlin, Ph.D. – President & CEO

As President & CEO, Dr. Bowlin is responsible for general management, financing and the strategic direction of the company. Dr. Bowlin has had a distinguished career encompassing over twenty years of anti-infective research, development, and management experience with pharmaceutical and biotechnology companies. Dr. Bowlin has extensive experience in drug discovery and development. Previously, Dr. Bowlin held the positions of Vice President, Research, at BioChem Pharma, and Director of Immunology at Marion Merrell Dow. Dr. Bowlin’s postdoctoral research was done at National Institutes of Health, and predoctoral research at the Cleveland Clinic. Dr. Bowlin holds a Ph.D. in Cell Biology/Immunology from Cleveland State University.

Donald T. Moir, Ph.D. – Chief Scientific Officer

As Chief Scientific Officer, Dr. Moir provides scientific leadership and direction to Microbiotix and is responsible for overseeing all research, drug development activities and scientific collaborations. Dr. Moir’s twenty-five year career has spanned a wide range of molecular biology, encompassing the discovery and validation of antibacterial drug targets, antibacterial drug discovery, bacterial diagnostic marker discovery, human genome physical mapping and cDNA mapping, the discovery of human markers for drug metabolism, and the cloning and expression of heterologous genes in the yeast S. cerevisiae. Previously, Dr. Moir held the positions of Research Director and Scientific Advisor at Genome Therapeutics Corporation. Dr. Moir received a Ph.D. in Biological Chemistry from Harvard University and a B.S. in Chemistry from the University of North Carolina at Chapel Hill. He has authored nearly 50 manuscripts and patent applications.